Clinical Trial Update: Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial update for amrubicin in elderly patients with extensive-disease small-cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Amrubicin (amrubicin)

Snippet

Sponsor: Sumitomo Pharma Co., Ltd. | Conditions: Small-cell Lung Cancer | Phase 3 | Status: TERMINATED